Srilata Puru Naik1, Mahesh P A2, Jayaraj B S2, SubbaRao V Madhunapantula3, Sarah Raeiszadeh Jahromi4, Manish Kumar Yadav3,5. 1. a Department of Pulmonary Medicine , B.G.S Global Institute of Medical Sciences, BGS Health & Education City , Bengaluru , Karnataka , India. 2. b Department of Pulmonary Medicine , JSS Medical College, JSS University , Mysuru , India. 3. c Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, J.S.S Medical College, JSS University , Mysuru , Karnataka , India. 4. d Genetics and Genomics Lab, Department of Studies in Genetics and Genomics, University of Mysore , Mysuru , Karnataka , India. 5. e Department of Biochemistry , JSS Medical College, JSS University , Mysore , Karnataka , India.
Abstract
INTRODUCTION: Even though IL-6 and MMP-9 are associated with airway inflammation in asthma, there is paucity of data in Indian population. OBJECTIVE: To determine the levels of IL-6 and MMP-9 in the serum of patients suffering from asthma, and correlate with (a) disease severity, as per GINA guidelines; (b) clinical phenotypes; and (c) response to treatment. METHODOLOGY: The levels of IL-6 and MMP-9 were compared between moderate persistent asthma (n = 25), severe persistent asthma (n = 25) and normal controls (n = 30). IL-6 and MMP-9 were measured by ELISA (R&D Systems Inc., USA and Canada) and compared between controls and asthmatics and between groups of different asthma severity, clinical variables, spirometry, and allergen sensitization. Spirometry was repeated after 2 months of ICS+LABA to assess response to treatment in relation to baseline IL-6 and MMP-9 levels. RESULTS: We observed a significant difference in both IL-6 and MMP-9 levels among asthmatics versus controls (p < 0.001), moderate versus severe persistent asthma (p < 0.001). A significant negative correlation was observed between MMP-9 and pre-bronchodilator FEV1 and FVC, but not with IL-6. There was no association between IL-6 and MMP-9 with asthma duration, total IgE, AEC, number of allergens sensitized and degree of sensitization. No significant correlation (p > 0.5) was observed with IL-6 and MMP-9 levels and FEV1 improvement after 2 months of ICS+LABA. CONCLUSION: Higher levels of IL-6 and MMP-9 were observed in asthmatics as compared to controls and in severe persistent asthma as compared to moderate persistent asthma, higher levels of MMP-9 was associated with lower lung functions.
INTRODUCTION: Even though IL-6 and MMP-9 are associated with airway inflammation in asthma, there is paucity of data in Indian population. OBJECTIVE: To determine the levels of IL-6 and MMP-9 in the serum of patients suffering from asthma, and correlate with (a) disease severity, as per GINA guidelines; (b) clinical phenotypes; and (c) response to treatment. METHODOLOGY: The levels of IL-6 and MMP-9 were compared between moderate persistent asthma (n = 25), severe persistent asthma (n = 25) and normal controls (n = 30). IL-6 and MMP-9 were measured by ELISA (R&D Systems Inc., USA and Canada) and compared between controls and asthmatics and between groups of different asthma severity, clinical variables, spirometry, and allergen sensitization. Spirometry was repeated after 2 months of ICS+LABA to assess response to treatment in relation to baseline IL-6 and MMP-9 levels. RESULTS: We observed a significant difference in both IL-6 and MMP-9 levels among asthmatics versus controls (p < 0.001), moderate versus severe persistent asthma (p < 0.001). A significant negative correlation was observed between MMP-9 and pre-bronchodilator FEV1 and FVC, but not with IL-6. There was no association between IL-6 and MMP-9 with asthma duration, total IgE, AEC, number of allergens sensitized and degree of sensitization. No significant correlation (p > 0.5) was observed with IL-6 and MMP-9 levels and FEV1 improvement after 2 months of ICS+LABA. CONCLUSION: Higher levels of IL-6 and MMP-9 were observed in asthmatics as compared to controls and in severe persistent asthma as compared to moderate persistent asthma, higher levels of MMP-9 was associated with lower lung functions.
Authors: Aivaras Cepelis; Ben M Brumpton; Lars E Laugsand; Håvard Dalen; Arnulf Langhammer; Imre Janszky; Linn B Strand Journal: Eur J Epidemiol Date: 2019-09-11 Impact factor: 8.082
Authors: Kathleen M Navarro; Corey R Butler; Kenneth Fent; Christine Toennis; Deborah Sammons; Alejandra Ramirez-Cardenas; Kathleen A Clark; David C Byrne; Pamela S Graydon; Christa R Hale; Andrea F Wilkinson; Denise L Smith; Marissa C Alexander-Scott; Lynne E Pinkerton; Judith Eisenberg; Joseph W Domitrovich Journal: Ann Work Expo Health Date: 2022-07-02 Impact factor: 2.779
Authors: Aivaras Cepelis; Ben M Brumpton; Vegard Malmo; Lars E Laugsand; Jan Pål Loennechen; Hanne Ellekjær; Arnulf Langhammer; Imre Janszky; Linn B Strand Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676